Boston Scientific Corporation

US$42.75As of Sun 8 Nov 2026, 12:00 UTC
NYSE:BSXHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 6.85%
Div yield —
ROE 14.12%
Medical Devices
Beta (5Y) 0.58
PE TTM 18.05
TSR TTM (57.56%)
Mkt cap US$61.96B
ROIC 10.62%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$54
25.99%
(96.74%)
Hold 2|8|8|11|12
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.51
0.56
0.60
0.63
3.71%
13.38%
22.41%
31.55%
Revenue$B
3.649
3.586
3.781
3.836
5.10%
1.68%
7.64%
6.86%
Peers (US$61.96B)
Cap (US$)
PE
124.1B
34.70x
Capital
TTM
5Y
10Y
Leveragex
4.587
2.166
1.873
EBIT/Intx
1.772
0.053
0.048
Own earn%
596.19
(77.12)
(64.80)
Sh yield%
36.35
28.43
28.43
Owners
Insiders/Inst%
10.24
33.50
Short interest%
5.54
SBC / revenue%
2.65
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
17
Op margin range%
15–18
$1 testx
0.1
Incr. ROIC%
2

Boston Scientific Corporation develops, manufactures and markets medical devices for interventional medical specialties worldwide through its MedSurg and Cardiovascular segments. Its products diagnose and treat gastrointestinal and urological conditions, neurological movement disorders, chronic pain, heart rate and rhythm disorders, peripheral arterial and venous diseases and cancer, and include implantable cardiac devices.